Shire PLC (NASDAQ:SHPG) Given a $222.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $222.00 price objective on Shire PLC (NASDAQ:SHPG) in a report issued on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also commented on the stock. ValuEngine raised shares of Shire PLC from a hold rating to a buy rating in a research report on Thursday, July 6th. HSBC Holdings plc raised shares of Shire PLC from a reduce rating to a hold rating in a research report on Thursday, July 6th. BidaskClub lowered shares of Shire PLC from a hold rating to a sell rating in a research report on Saturday, July 1st. Stifel Nicolaus reduced their target price on shares of Shire PLC from $250.00 to $245.00 and set a buy rating for the company in a research note on Friday, June 9th. Finally, Jefferies Group LLC reiterated a buy rating and issued a $216.00 target price (down previously from $239.00) on shares of Shire PLC in a research note on Friday, June 9th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and seventeen have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus price target of $227.45.

Shares of Shire PLC (SHPG) traded up 0.06% on Tuesday, reaching $163.32. 987,651 shares of the company were exchanged. Shire PLC has a 12-month low of $158.88 and a 12-month high of $209.22.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $3.63 EPS for the quarter, topping the consensus estimate of $3.22 by $0.41. The business had revenue of $3.57 billion for the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The business’s revenue was up 109.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.12 EPS. Equities research analysts expect that Shire PLC will post $14.88 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Shire PLC (NASDAQ:SHPG) Given a $222.00 Price Target at Cantor Fitzgerald” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.tickerreport.com/banking-finance/2722847/shire-plc-nasdaqshpg-given-a-222-00-price-target-at-cantor-fitzgerald.html.

A number of institutional investors have recently added to or reduced their stakes in the company. Whittier Trust Co. boosted its position in Shire PLC by 19.1% in the first quarter. Whittier Trust Co. now owns 573 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 92 shares in the last quarter. Pinnacle Bank bought a new position in Shire PLC during the first quarter worth approximately $101,000. Thompson Davis & CO. Inc. boosted its position in Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 19 shares in the last quarter. North Star Investment Management Corp. boosted its position in Shire PLC by 8.5% in the first quarter. North Star Investment Management Corp. now owns 756 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 59 shares in the last quarter. Finally, FTB Advisors Inc. boosted its position in Shire PLC by 11.1% in the first quarter. FTB Advisors Inc. now owns 749 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 75 shares in the last quarter. 21.06% of the stock is owned by institutional investors and hedge funds.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Analyst Recommendations for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.